70 related articles for article (PubMed ID: 35313664)
1. Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant.
Jullien M; Coste-Burel M; Clemenceau B; Letailleur V; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Imbert BM; Ollier J; Grain A; Touzeau C; Moreau P; Béné MC; Vié H; Chevallier P
EJHaem; 2022 May; 3(2):484-487. PubMed ID: 35313664
[TBL] [Abstract][Full Text] [Related]
2. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
3. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
[TBL] [Abstract][Full Text] [Related]
4. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
[TBL] [Abstract][Full Text] [Related]
5. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine.
Clémenceau B; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Le Bourgeois A; Jullien M; Ollier J; Grain A; Béné MC; Vié H; Chevallier P
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335079
[TBL] [Abstract][Full Text] [Related]
7. Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients.
Lindemann M; Klisanin V; Thümmler L; Fisenkci N; Tsachakis-Mück N; Ditschkowski M; Schwarzkopf S; Klump H; Reinhardt HC; Horn PA; Koldehoff M
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696183
[TBL] [Abstract][Full Text] [Related]
8. HLA-DP diversity is associated with improved response to SARS-Cov-2 vaccine in hematopoietic stem cell transplant recipients.
Villemonteix J; Allain V; Verstraete E; Jorge-Cordeiro D; Socié G; Xhaard A; Feray C; Caillat-Zucman S
iScience; 2023 May; 26(5):106763. PubMed ID: 37168557
[TBL] [Abstract][Full Text] [Related]
9. Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination.
Rodríguez-Mora S; Pérez-Lamas L; Sainero MS; Torres M; Sánchez-Menéndez C; Corona M; Mateos E; Casado-Fernández G; Alcamí J; García-Pérez J; Pérez-Olmeda M; Murciano-Antón MA; López-Jiménez J; García-Gutiérrez V; Coiras M
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190272
[TBL] [Abstract][Full Text] [Related]
10. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.
Leclerc M; Redjoul R; Le Bouter A; Beckerich F; Robin C; Parinet V; Pautas C; Menouche D; Bouledroua S; Roy L; Cabanne L; Nait-Sidenas Y; Fourati S; Maury S
J Hematol Oncol; 2022 Mar; 15(1):27. PubMed ID: 35303906
[TBL] [Abstract][Full Text] [Related]
11. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
12. Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
Shahzad M; Chaudhary SG; Zafar MU; Hassan MA; Hussain A; Ali F; Anwar I; Ahmed M; Ahmed N; Khurana S; Rauf MA; Anwar F; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
Transpl Infect Dis; 2022 Apr; 24(2):e13792. PubMed ID: 35030267
[TBL] [Abstract][Full Text] [Related]
13. Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant.
VanOudenhove J; Liu Y; Nelakanti R; Kim D; Busarello E; Ovalle NT; Qi Z; Mamillapalli P; Siddon A; Bai Z; Axtmayer A; Corso C; Kothari S; Foss F; Isufi I; Tebaldi T; Gowda L; Fan R; Seropian S; Halene S
bioRxiv; 2023 Oct; ():. PubMed ID: 37961434
[TBL] [Abstract][Full Text] [Related]
14. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
[TBL] [Abstract][Full Text] [Related]
15. Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity.
Sherman AC; Desjardins M; Cheng CA; Bausk B; Izaguirre N; Zhou G; Krauss J; Tolan N; Walt DR; Soiffer R; Ho VT; Issa NC; Baden LR
Clin Infect Dis; 2022 Aug; 75(1):e920-e923. PubMed ID: 34726754
[TBL] [Abstract][Full Text] [Related]
16. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation in the COVID-19 era.
Bordat J; Maury S; Leclerc M
Front Immunol; 2023; 14():1100468. PubMed ID: 36911678
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
19. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
20. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients.
Chiarucci M; Paolasini S; Isidori A; Guiducci B; Loscocco F; Capalbo M; Visani G
Front Oncol; 2021; 11():737300. PubMed ID: 34552880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
